Apellis Pharmaceuticals (APLS) PT Raised to $46 at BofA Securities
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Price: $41.03 --0%
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
BofA Securities analyst Tazeen Ahmad raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $46.00 (from $44.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
- Sinclair Broadcasting (SBGI) PT Raised to $15 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
